

ANIKA THERAPEUTICS INC  
Form 8-K  
February 15, 2011

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): **February 14, 2011**

**Anika Therapeutics, Inc.**  
(Exact Name of Registrant as Specified in Its Charter)

**Massachusetts**    **000-21326**    **04-3145961**  
(State or Other Jurisdiction of Incorporation)    (Commission File Number)    (I.R.S. Employer Identification No.)

**32 Wiggins Avenue, Bedford, Massachusetts**    **01730**  
(Address of Principal Executive Offices)                                  (Zip Code)

Registrant's Telephone Number, Including Area Code: **(781) 457-9000**

**N/A**  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events.**

On February 14, 2011, Anika Therapeutics, Inc. issued a press release announcing the date of its fourth-quarter and year-end financial results conference call and providing a regulatory timing update. A copy of the press release is filed as Exhibit 99.1 hereto and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release issued by Anika Therapeutics, Inc. on February 14, 2011

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ANIKA THERAPEUTICS,  
INC.

February 15, 2011 By: /s/ Kevin W. Quinlan  
Kevin W. Quinlan  
*Chief Financial Officer*

---

**Exhibit Index**

**Exhibit No. Description**

99.1 Press Release issued by Anika Therapeutics, Inc. on February 14, 2011